Search

Your search keyword '"Karlin, Lionel"' showing total 1,014 results
Start Over Author "Karlin, Lionel"
1,014 results on '"Karlin, Lionel"'

1. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Author

Leleu, Xavier, Hulin, Cyrille, Lambert, Jerome, Bobin, Arthur, Perrot, Aurore, Karlin, Lionel, Roussel, Murielle, Montes, Lydia, Cherel, Brieuc, Chalopin, Thomas, Slama, Borhane, Chretien, Marie-Lorraine, Laribi, Kamel, Dingremont, Claire, Roul, Christophe, Mariette, Clara, Rigaudeau, Sophie, Calmettes, Claire, Dib, Mamoun, Tiab, Mourad, Vincent, Laure, Delaunay, Jacques, Santagostino, Alberto, Macro, Margaret, Bourgeois, Emmanuelle, Orsini-Piocelle, Frederique, Gay, Julie, Bareau, Benoit, Bigot, Noemie, Vergez, François, Lebreton, Pierre, Tabrizi, Reza, Waultier-Rascalou, Agathe, Frenzel, Laurent, Le Calloch, Ronan, Chalayer, Emilie, Braun, Thorsten, Lachenal, Florence, Corm, Selim, Kennel, Celine, Belkhir, Rakiba, Bladé, Jean-Sebastien, Joly, Bertrand, Richez-Olivier, Valentine, Gardeney, Helene, Demarquette, Helene, Robu-Cretu, Daniela, Garderet, Laurent, Newinger-Porte, Muriel, Kasmi, Amine, Royer, Bruno, Decaux, Olivier, Arnulf, Bertrand, Belhadj, Karim, Touzeau, Cyrille, Mohty, Mohamad, Manier, Salomon, Moreau, Philippe, Avet-Loiseau, Hervé, Corre, Jill, and Facon, Thierry

Published
2024
Full Text
View/download PDF

2. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

Author

Einsele, Hermann, Moreau, Philippe, Bahlis, Nizar, Bhutani, Manisha, Vincent, Laure, Karlin, Lionel, Perrot, Aurore, Goldschmidt, Hartmut, van de Donk, Niels W. C. J., Ocio, Enrique M., Martinez-Lopez, Joaquin, Rodríguez-Otero, Paula, Dytfeld, Dominik, Diels, Joris, Strulev, Vadim, Haddad, Imene, Renaud, Thomas, Ammann, Eric, Cabrieto, Jedelyn, Perualila, Nolen, Gan, Ryan, Zhang, Youyi, Parekh, Trilok, Albrecht, Claire, Weisel, Katja, and Mateos, Maria-Victoria

Published
2024
Full Text
View/download PDF

3. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Author

Touzeau, Cyrille, Krishnan, Amrita Y., Moreau, Philippe, Perrot, Aurore, Usmani, Saad Z., Manier, Salomon, Cavo, Michele, Martinez Chamorro, Carmen, Nooka, Ajay K., Martin, Thomas G., Karlin, Lionel, Leleu, Xavier, Bahlis, Nizar J., Besemer, Britta, Pei, Lixia, Stein, Sarah, Wang Lin, Shun Xin, Trancucci, Danielle, Verona, Raluca I., Girgis, Suzette, Miao, Xin, Uhlar, Clarissa M., Chastain, Katherine, and Garfall, Alfred L.

Published
2024
Full Text
View/download PDF

4. Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Author

Moreau, Philippe, Mateos, María-Victoria, Gonzalez Garcia, Maria Esther, Einsele, Hermann, De Stefano, Valerio, Karlin, Lionel, Lindsey-Hill, Joanne, Besemer, Britta, Vincent, Laure, Kirkpatrick, Suriya, Delforge, Michel, Perrot, Aurore, van de Donk, Niels W. C. J., Pawlyn, Charlotte, Manier, Salomon, Leleu, Xavier, Martinez-Lopez, Joaquin, Ghilotti, Francesca, Diels, Joris, Morano, Raúl, Albrecht, Claire, Strulev, Vadim, Haddad, Imène, Pei, Lixia, Kobos, Rachel, Smit, Jennifer, Slavcev, Mary, Marshall, Alexander, and Weisel, Katja

Published
2023
Full Text
View/download PDF

5. Teclistamab in Relapsed or Refractory Multiple Myeloma

Author

Moreau, Philippe, Garfall, Alfred L, van de Donk, Niels WCJ, Nahi, Hareth, San-Miguel, Jesús F, Oriol, Albert, Nooka, Ajay K, Martin, Thomas, Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Benboubker, Lotfi, Mateos, Maria-Victoria, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Sidana, Surbhi, Delforge, Michel, Pei, Lixia, Trancucci, Danielle, Verona, Raluca, Girgis, Suzette, Lin, Shun XW, Olyslager, Yunsi, Jaffe, Mindy, Uhlar, Clarissa, Stephenson, Tara, Van Rampelbergh, Rian, Banerjee, Arnob, Goldberg, Jenna D, Kobos, Rachel, Krishnan, Amrita, and Usmani, Saad Z

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Rare Diseases, Hematology, Immunotherapy, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Cancer, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, B-Cell Maturation Antigen, CD3 Complex, Humans, Injections, Subcutaneous, Multiple Myeloma, Neoplasm Recurrence, Local, Recurrence, T-Lymphocytes, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundTeclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma.MethodsIn this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better).ResultsAmong 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2).ConclusionsTeclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.).

Published
2022

6. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

Author

Moreau, Philippe, Hulin, Cyrille, Perrot, Aurore, Arnulf, Bertrand, Belhadj, Karim, Benboubker, Lotfi, Zweegman, Sonja, Caillon, Hélène, Caillot, Denis, Avet-Loiseau, Hervé, Delforge, Michel, Dejoie, Thomas, Facon, Thierry, Sonntag, Cécile, Fontan, Jean, Mohty, Mohamad, Jie, Kon-Siong, Karlin, Lionel, Kuhnowski, Frédérique, Lambert, Jérôme, Leleu, Xavier, Macro, Margaret, Orsini-Piocelle, Frédérique, Roussel, Murielle, Schiano de Colella, Jean Marc, van de Donk, Niels WCJ, Wuillème, Soraya, Broijl, Annemiek, Touzeau, Cyrille, Tiab, Mourad, Marolleau, Jean-Pierre, Meuleman, Nathalie, Vekemans, Marie-Christiane, Westerman, Matthijs, Klein, Saskia K, Levin, Mark-David, Offner, Fritz, Escoffre-Barbe, Martine, Eveillard, Jean-Richard, Garidi, Réda, Hua, Winnie, Wang, Jianping, Tuozzo, Alba, de Boer, Carla, Rowe, Melissa, Vanquickelberghe, Veronique, Carson, Robin, Vermeulen, Jessica, Corre, Jill, and Sonneveld, Pieter

Published
2024
Full Text
View/download PDF

7. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

Author

Ocio, Enrique M., Perrot, Aurore, Bories, Pierre, San-Miguel, Jesus F., Blau, Igor W., Karlin, Lionel, Martinez-Lopez, Joaquin, Wang, Song-Yau, Bringhen, Sara, Marcatti, Magda, Mateos, María-Victoria, Rodriguez-Otero, Paula, Oliva, Stefania, Nogai, Axel, Le Roux, Nadia, Dong, Liyan, Macé, Sandrine, Gassiot, Matthieu, Fitzmaurice, Thomas, Oprea, Corina, and Moreau, Philippe

Published
2023
Full Text
View/download PDF

8. Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study

Author

Jourdes, Aurélie, Cellerin, Elise, Touzeau, Cyrille, Harel, Stéphanie, Denis, Blandine, Escure, Guillaume, Faure, Emmanuel, Jamard, Simon, Danion, Francois, Sonntag, Cécile, Ader, Florence, Karlin, Lionel, Soueges, Sarah, Cazelles, Clarisse, de La Porte des Vaux, Clémentine, Frenzel, Laurent, Lanternier, Fanny, Brousse, Xavier, Cazaubiel, Titouan, Berger, Pierre, Collignon, Aude, Blot, Mathieu, Pieragostini, Andrea, Charles, Morgane, Chaleteix, Carine, Redor, Alexis, Roland, Virginie, Cartau, Tom, Macro, Margaret, Chalopin, Thomas, Vallet, Nicolas, Perrot, Aurore, and Martin-Blondel, Guillaume

Published
2024
Full Text
View/download PDF

10. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

Author

Martin, Thomas G., Moreau, Philippe, Usmani, Saad Z., Garfall, Alfred, Mateos, María-Victoria, San-Miguel, Jesús F., Oriol, Albert, Nooka, Ajay K., Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Krishnan, Amrita, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Delforge, Michel, Trancucci, Danielle, Pei, Lixia, Kobos, Rachel, Fastenau, John, Gries, Katharine S., and van de Donk, Niels W.C.J.

Published
2024
Full Text
View/download PDF

11. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

Author

Moreau, Philippe, van de Donk, Niels W. C. J., Delforge, Michel, Einsele, Hermann, De Stefano, Valerio, Perrot, Aurore, Besemer, Britta, Pawlyn, Charlotte, Karlin, Lionel, Manier, Salomon, Leleu, Xavier, Weisel, Katja, Ghilotti, Francesca, Diels, Joris, Elsada, Ahmed, Morano, Raul, Strulev, Vadim, Pei, Lixia, Kobos, Rachel, Smit, Jennifer, Slavcev, Mary, and Mateos, Maria-Victoria

Published
2023
Full Text
View/download PDF

12. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Author

Moreau, Philippe, Chari, Ajai, Oriol, Albert, Martinez-Lopez, Joaquin, Haenel, Mathias, Touzeau, Cyrille, Ailawadhi, Sikander, Besemer, Britta, de la Rubia Comos, Javier, Encinas, Cristina, Mateos, Maria-Victoria, Salwender, Hans, Rodriguez-Otero, Paula, Hulin, Cyrille, Karlin, Lionel, Sureda Balari, Anna, Bargay, Joan, Benboubker, Lotfi, Rosiñol, Laura, Tarantolo, Stefano, Terebelo, Howard, Yang, Shiyi, Wang, Jianping, Nnane, Ivo, Qi, Ming, Kosh, Michele, Delioukina, Maria, and Goldschmidt, Hartmut

Published
2023
Full Text
View/download PDF

13. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.

Author

Perrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad, Kumar, Shaji, Bahlis, Nizar, Hulin, Cyrille, Orlowski, Robert, Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, He, Jianming, Ho, Kai, Van Rampelbergh, Rian, Uhlar, Clarissa, Wang, Jianping, Kobos, Rachel, Gries, Katharine, Fastenau, John, and Weisel, Katja

Subjects
Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Lenalidomide, Male, Middle Aged, Multiple Myeloma, Pain Measurement, Patient Reported Outcome Measures, Quality of Life, Time Factors, Treatment Outcome
Abstract

PURPOSE: To evaluate the effects of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) on patient-reported outcomes (PROs) in the phase III MAIA study. PATIENTS AND METHODS: PROs were assessed on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item and the EuroQol 5-dimensional descriptive system at baseline and every 3 months during treatment. By mixed-effects model, changes from baseline are presented as least squares means with 95% CIs. RESULTS: A total of 737 transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma were randomly assigned to D-Rd (n = 368) or Rd (n = 369). Compliance with PRO assessments was high at baseline (> 90%) through month 12 (> 78%) for both groups. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item global health status scores improved from baseline in both groups and were consistently greater with D-Rd at all time points. A global health status benefit was achieved with D-Rd, regardless of age (< 75 and ≥ 75 years), baseline Eastern Cooperative Oncology Group (ECOG) performance status score, or depth of response. D-Rd treatment resulted in significantly greater reduction in pain scores as early as cycle 3 (P = .0007 v Rd); the magnitude of change was sustained through cycle 12. Reductions in pain with D-Rd were clinically meaningful in patients regardless of age, ECOG status, or depth of response. Similarly, PRO improvements were observed with D-Rd and Rd on the EuroQol 5-dimensional descriptive system visual analog scale score. CONCLUSION: D-Rd compared with Rd was associated with faster and sustained clinically meaningful improvements in PROs, including pain, in transplant-ineligible patients with newly diagnosed multiple myeloma regardless of age, baseline ECOG status, or depth of treatment response.

Published
2021

15. HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma

Author

Bourbon, Estelle, Sesques, Pierre, Gossez, Morgane, Tordo, Jérémie, Ferrant, Emmanuelle, Safar, Violaine, Wallet, Florent, Aussedat, Guillaume, Maarek, Alizée, Bouafia, Fadhela, Karlin, Lionel, Ghergus, Dana, Golfier, Camille, Lequeu, Hélène, Lazareth, Anne, Schwiertz, Vérane, Viel, Sébastien, Idlhaj, Maryam, Ghesquières, Hervé, Monneret, Guillaume, Bachy, Emmanuel, and Venet, Fabienne

Published
2023
Full Text
View/download PDF

17. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Author

Roussel, Murielle, Lauwers-Cances, Valérie, Macro, Margaret, Leleu, Xavier, Royer, Bruno, Hulin, Cyrille, Karlin, Lionel, Perrot, Aurore, Touzeau, Cyrille, Chrétien, Marie-Lorraine, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Mariette, Clara, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean-Valère, Jaccard, Arnaud, Lenain, Pascal, Borel, Cécile, Hebraud, Benjamin, Benbrahim, Omar, Dorvaux, Véronique, Manier, Salomon, Augeul-Meunier, Karine, Vekemans, Marie-Christiane, Randriamalala, Edouard, Chaoui, Driss, Caers, Jo, Chaleteix, Carine, Benboubker, Lofti, Vincent, Laure, Glaisner, Sylvie, Zunic, Patricia, Slama, Borhane, Eveillard, Jean-Richard, Humbrecht-Kraut, Catherine, Morel, Véronique, Mineur, Philippe, Eisenmann, Jean-Claude, Demarquette, Hélène, Richez, Valentine, Vignon, Marguerite, Caillot, Denis, Facon, Thierry, Moreau, Philippe, Colin, Anne-Laurène, Olivier, Pascale, Wuilleme, Soraya, Avet-Loiseau, Hervé, Corre, Jill, and Attal, Michel

Published
2022
Full Text
View/download PDF

18. End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy.

Author

Sesques, Pierre, Karlin, Lionel, Massy, Emmanuel, Maarek, Alizée, Aussedat, Guillaume, Lazareth, Anne, Golfier, Camille, Bouafia-Sauvy, Fadhela, Lequeu, Helene, Ghergus, Dana, Safar, Violaine, Ferrant, Emmanuelle, Bachy, Emmanuel, Ghesquières, Hervé, Confavreux, Cyrille B., Demangel, Delphine, Perrial, Emeline, and Dumontet, Charles

Subjects
TIME of death, MULTIPLE myeloma, DISEASE progression, CAUSES of death, KIDNEY failure
Abstract

Background: In spite of spectacular advances in the treatment of multiple myeloma, a majority of patients will die from this disease or related complications. While a great amount of focus has been dedicated to the development of novel therapies, little attention has been paid to latter stages of patient follow-up. Patients and methods: In order to describe patient management during this critical period as well as the immediate causes and circumstances of death, we have analyzed a single center series of 100 patients diagnosed with myeloma who died between 2016 and 2021. Results: Patients received a median of 3 lines of treatment, including 2 during their last year of life. Sixty per cent of patients had received daratumumab. Fifty patients had obtained complete remission or very good partial response at some time during the course of disease but 75 were refractory to the last treatment line. Eighteen patients died while their disease was stable or in remission while 77 had confirmed progressive disease at time of death. Thirty six patients had uncontrolled sepsis, 49 were in renal failure and 24 had hypercalcemia at the time of death. Seventy three patients presented with lymphopenia. Disease progression was documented in a majority of MM patients at the time of death and was associated with disease-related complications in a significant number of patients. Conclusion: Disease progression remains the main cause of death in patients with multiple myeloma. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

Author

Schjesvold, Fredrik, Delimpasi, Sosana, Robak, Pawel, Coriu, Daniel, Nikolayeva, Anna, Tomczak, Waldemar, Pour, Ludek, Spicka, Ivan, Dimopoulos, Meletios-Athanasios, Masszi, Tamas, Doronin, Vadim, Minarik, Jiri, Salogub, Galina, Alekseeva, Yulia, Maisnar, Vladimir, Mikala, Gabor, Rosinol, Laura, Konstantinova, Tatiana, Lazzaro, Antonio, Liberati, Anna Marina, Symeonidis, Anargyros, Gatt, Moshe, Illes, Arpad, Abdulhaq, Haifaa, Dungarwalla, Moez, Grosicki, Sebastian, Hajek, Roman, Leleu, Xavier, Myasnikov, Alexander, Richardson, Paul G., Avivi, Irit, Deeren, Dries, Gironella, Mercedes, Hernandez-Garcia, Miguel Teodoro, Martinez Lopez, Joaquin, Newinger-Porte, Muriel, Ribas, Paz, Samoilova, Olga, Voog, Eric, Arnao-Herraiz, Mario, Carrillo-Cruz, Estrella, Corradini, Paolo, Dodlapati, Jyothi, Granell Gorrochategui, Miquel, Huang, Shang-Yi, Jenner, Matthew, Karlin, Lionel, Kim, Jin Seok, Kopacz, Agnieszka, Medvedeva, Nadezhda, Min, Chang-Ki, Mina, Roberto, Palk, Katrin, Shin, Ho-Jin, Sohn, Sang Kyun, Sonneveld, Pieter, Tache, Jason, Anagnostopoulos, Achilles, Arguiñano, Jose-Maria, Cavo, Michele, Filicko, Joanne, Garnes, Margaret, Halka, Janusz, Herzog-Tzarfati, Kathrin, Ipatova, Natalia, Kim, Kihyun, Krauth, Maria-Theresa, Kryuchkova, Irina, Lazaroiu, Mihaela Cornelia, Luppi, Mario, Proydakov, Andrei, Rambaldi, Alessandro, Rudzianskiene, Milda, Yeh, Su-Peng, Alcalá-Peña, Maria Magdalena, Alegre Amor, Adrian, Alizadeh, Hussain, Bendandi, Maurizio, Brearton, Gillian, Brown, Randall, Cavet, Jim, Dally, Najib, Egyed, Miklos, Hernández-Rivas, José Ángel, Kaare, Ain, Karsenti, Jean-Michel, Kloczko, Janusz, Kreisle, William, Lee, Je-Jung, Legiec, Wojciech, Machherndl-Spandl, Sigrid, Manda, Sudhir, Mateos, Maria-Victoria, Moiseev, Ivan, Moreb, Jan, Nagy, Zsolt, Nair, Santosh, Oriol-Rocafiguera, Albert, Osswald, Michael, Otero-Rodriguez, Paula, Peceliunas, Valdas, Plesner, Torben, Rey, Philippe, Rossi, Giuseppe, Stevens, Don, Suriu, Celia, Tarella, Corrado, Verlinden, Anke, Zannetti, Alain, Schjesvold, Fredrik H, Pour, Luděk, Špička, Ivan, Mikala, Gábor, Rosiñol, Laura, Symeonidis, Argiris, Moody, Victoria, Thuresson, Marcus, Byrne, Catriona, Harmenberg, Johan, Bakker, Nicolaas A, Hájek, Roman, and Richardson, Paul G

Published
2022
Full Text
View/download PDF

21. Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

Author

Bobin, Arthur, Kyheng, Maéva, Guidez, Stéphanie, Gruchet-Merouze, Cécile, Richez, Valentine, Duhamel, Alain, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, Malfuson, Jean-Valère, Bourquard, Pascal, Lenain, Pascal, Perrot, Aurore, Roussel, Murielle, Jaccard, Arnaud, Petillon, Marie-Odile, Belhadj-Merzoug, Karim, Chretien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frédérique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Roos-Weil, Damien, Eisenmann, Jean Claude, Dorvaux, Véronique, Voog, Eric G., Moreau, Philippe, Avet-Loiseau, Hervé, Hulin, Cyrille, Facon, Thierry, and Leleu, Xavier

Published
2022
Full Text
View/download PDF

22. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Author

Kreitman, Robert, Dearden, Claire, Zinzani, Pier, Delgado, Julio, Karlin, Lionel, Robak, Tadeusz, Gladstone, Douglas, le Coutre, Philipp, Dietrich, Sascha, Gotic, Mirjana, Larratt, Loree, Offner, Fritz, Schiller, Gary, Swords, Ronan, Bacon, Larry, Bocchia, Monica, Bouabdallah, Krimo, Breems, Dimitri, Cortelezzi, Agostino, Dinner, Shira, Doubek, Michael, Gjertsen, Bjorn, Gobbi, Marco, Hellmann, Andrzej, Lepretre, Stephane, Maloisel, Frederic, Ravandi, Farhad, Rousselot, Philippe, Rummel, Mathias, Siddiqi, Tanya, Tadmor, Tamar, Troussard, Xavier, Yi, Cecilia, Saglio, Giuseppe, Roboz, Gail, Balic, Kemal, Standifer, Nathan, He, Peng, Marshall, Shannon, Wilson, Wyndham, Pastan, Ira, Yao, Nai-Shun, and Giles, Francis

Subjects
Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Bacterial Toxins, Drug Resistance, Neoplasm, Exotoxins, Female, Follow-Up Studies, Humans, Leukemia, Hairy Cell, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Remission Induction, Salvage Therapy, Survival Rate
Abstract

This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. The study enrolled patients with relapsed/refractory HCL who had ≥2 prior systemic therapies, including ≥1 purine nucleoside analog. Patients received moxetumomab pasudotox 40 µg/kg intravenously on days 1, 3, and 5 every 28 days for ≤6 cycles. Blinded independent central review determined disease response and minimal residual disease (MRD) status. Among 80 patients (79% males; median age, 60.0 years), durable complete response (CR) rate was 30%, CR rate was 41%, and objective response rate (CR and partial response) was 75%; 64 patients (80%) achieved hematologic remission. Among complete responders, 27 (85%) achieved MRD negativity by immunohistochemistry. The most frequent adverse events (AEs) were peripheral edema (39%), nausea (35%), fatigue (34%), and headache (33%). Treatment-related serious AEs of hemolytic uremic syndrome (7.5%) and capillary leak syndrome (5%) were reversible and generally manageable with supportive care and treatment discontinuation (6 patients; 7.5%). Moxetumomab pasudotox treatment achieved a high rate of independently assessed durable response and MRD eradication in heavily pretreated patients with HCL, with acceptable tolerability.

Published
2018

23. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real‐world: The retrospective IMAGE study

Author

Decaux, Olivier, primary, Fontan, Jean, additional, Perrot, Aurore, additional, Karlin, Lionel, additional, Touzeau, Cyrille, additional, Schulmann, Samantha, additional, Manier, Salomon, additional, Belhadj, Karim, additional, Trebouet, Adrien, additional, Zunic, Patricia, additional, Schiano De Colella, Jean‐Marc, additional, Castel, Brice, additional, Van De Wyngaert, Zoé, additional, Pica, Gian Matteo, additional, Tiab, Mourad, additional, Kuhnowski, Frédérique, additional, Bouketouche, Malek, additional, Rigaudeau, Sophia, additional, Benramdane, Riad, additional, Tekle, Christina, additional, Lafore, Radhia, additional, Gaucher, Marianne, additional, Corre, Jill, additional, and Leleu, Xavier, additional

Published
2024
Full Text
View/download PDF

24. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Author

Moreau, Philippe, Hulin, Cyrille, Perrot, Aurore, Arnulf, Bertrand, Belhadj, Karim, Benboubker, Lotfi, Béné, Marie C, Zweegman, Sonja, Caillon, Hélène, Caillot, Denis, Corre, Jill, Delforge, Michel, Dejoie, Thomas, Doyen, Chantal, Facon, Thierry, Sonntag, Cécile, Fontan, Jean, Mohty, Mohamad, Jie, Kon-Siong, Karlin, Lionel, Kuhnowski, Frédérique, Lambert, Jérôme, Leleu, Xavier, Macro, Margaret, Orsini-Piocelle, Frédérique, Roussel, Murielle, Stoppa, Anne-Marie, van de Donk, Niels W C J, Wuillème, Soraya, Broijl, Annemiek, Touzeau, Cyrille, Tiab, Mourad, Marolleau, Jean-Pierre, Meuleman, Nathalie, Vekemans, Marie-Christiane, Westerman, Matthijs, Klein, Saskia K, Levin, Mark-David, Offner, Fritz, Escoffre-Barbe, Martine, Eveillard, Jean-Richard, Garidi, Réda, Ahmadi, Tahamtan, Krevvata, Maria, Zhang, Ke, de Boer, Carla, Vara, Sanjay, Kampfenkel, Tobias, Vanquickelberghe, Veronique, Vermeulen, Jessica, Avet-Loiseau, Hervé, and Sonneveld, Pieter

Published
2021
Full Text
View/download PDF

25. Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified

Author

Bourbon, Estelle, Maucort-Boulch, Delphine, Fontaine, Juliette, Mauduit, Claire, Sesques, Pierre, Safar, Violaine, Ferrant, Emmanuelle, Golfier, Camille, Ghergus, Dana, Karlin, Lionel, Lazareth, Anne, Bouafia, Fadhela, Pica, Gian Matteo, Orsini-Piocelle, Frédérique, Rocher, Clément, Gros, François-Xavier, Parrens, Marie, Dony, Arthur, Rossi, Cédric, Ghesquières, Hervé, Bachy, Emmanuel, Traverse-Glehen, Alexandra, and Sarkozy, Clémentine

Published
2021
Full Text
View/download PDF

26. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Author

Usmani, Saad Z, Garfall, Alfred L, van de Donk, Niels W C J, Nahi, Hareth, San-Miguel, Jesus F, Oriol, Albert, Rosinol, Laura, Chari, Ajai, Bhutani, Manisha, Karlin, Lionel, Benboubker, Lotfi, Pei, Lixia, Verona, Raluca, Girgis, Suzette, Stephenson, Tara, Elsayed, Yusri, Infante, Jeffrey, Goldberg, Jenna D, Banerjee, Arnob, Mateos, María-Victoria, and Krishnan, Amrita

Published
2021
Full Text
View/download PDF

27. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Author

Gabriel Tremblay, Patrick Daniele, Janis Breeze, Lingling Li, Jatin Shah, Sharon Shacham, Michael Kauffman, Monika Engelhardt, Ajaj Chari, Ajay Nooka, Dan Vogl, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Paul Richardson, Noa Biran, David Siegel, Philip Vlummens, Chantal Doyen, Thierry Facon, Mohamad Mohty, Nathalie Meuleman, Moshe Levy, Luciano Costa, James E. Hoffman, Michel Delforge, David Kaminetzky, Katja Weisel, Marc Raab, David Dingli, Sascha Tuchman, Frenzel Laurent, Ravi Vij, Gary Schiller, Philippe Moreau, Joshua Richter, Martin Schreder, Klaus Podar, Terri Parker, Robert Frank Cornell, Karlin Lionel, Sylvain Choquet, and Jagannath Sundar

Subjects
Patient reported outcomes, Health-related quality of life, FACT-MM, Multiple myeloma, Selinexor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Selinexor is an oral, selective nuclear export inhibitor. STORM was a phase 2b, single-arm, open-label, multicenter trial of selinexor with low dose dexamethasone in patients with penta-exposed relapsed/refractory multiple myeloma (RRMM) that met its primary endpoint, with overall response of 26% (95% confidence interval [CI], 19 to 35%). Health-related quality of life (HRQoL) was a secondary endpoint measured using the Functional Assessment of Cancer Therapy – Multiple Myeloma (FACT-MM). This study examines impact of selinexor treatment on HRQoL of patients treated in STORM and reports two approaches to calculate minimal clinically important differences for the FACT-MM. Methods FACT-MM data were collected at baseline, on day 1 of each 4-week treatment cycle, and at end of treatment (EOT). Changes from baseline were analyzed for the FACT-MM total score, FACT-trial outcome index (TOI), FACT-General (FACT-G), and the MM-specific domain using mixed-effects regression models. Two approaches for evaluating minimal clinically important differences were explored: the first defined as 10% of the instrument range, and the second based on estimated mean baseline differences between Eastern Cooperative Oncology Group performance status (ECOG PS) scores. Post-hoc difference analysis compared change in scores from baseline to EOT for treatment responders and non-responders. Results Eighty patients were included in the analysis; the mean number of prior therapies was 7.9 (standard deviation [SD] 3.1), and mean duration of myeloma was 7.6 years (SD 3.4). Each exploratory minimal clinically important difference threshold yielded consistent results whereby most patients did not experience HRQoL decline during the first six cycles of treatment (range: 53.9 to 75.7% for the first approach; range: 52.6 to 72.9% for the second). Treatment responders experienced less decline in HRQoL from baseline to EOT than non-responders, which was significant for the FACT-G, but not for other scores. Conclusion The majority of patients did not experience decline in HRQoL based on minimal clinically important differences during early cycles of treatment with selinexor and dexamethasone in the STORM trial. An anchor-based approach utilizing patient-level data (ECOG PS score) to define minimal clinically important differences for the FACT-MM gave consistent results with a distribution-based approach. Trial registration This trial was registered on ClinicalTrials.gov under the trial-ID NCT02336815 on January 8, 2015.

Published
2021
Full Text
View/download PDF

28. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Author

Alegre Amor, Adrian, Baldini, Luca, Beksac, Meral, Belotti, Angelo, Benboubker, Lotfi, Besemer, Britta, Besisik, Sevgi, Bila, Jelena, Boccadoro, Mario, Cavo, Michele, De La Rubia Comos, Javier, Delimpasi, Sosana, Dimopoulos, Meletios A., Doyen, Chantal, Dytfeld, Dominik, Engelhardt, Monika, Facon, Thierry, Foà, Roberto, Goldschmidt, Hartmut, Grosicki, Sebastian, Hajek, Roman, Hayri Ozsan, Guner, Hulin, Cyrille, Iversen, Brian, Karlin, Lionel, Katodritou, Eirini, Knop, Stefan, Kyrtsonis, Marie-Christine, Lahuerta, Juan Jose, Leleu, Xavier, Martinez Chamorro, Carmen, Mateos Manteca, María-Victoria, Meuleman, Nathalie, Minnema, Monique, Moreau, Philippe, Offidani, Massino, Oriol Rocafiguera, Albert, Pehlivan, Mustafa, Pour, Ludek, Roerdink, Henk Th.J., Rosinol Dacsh, Laura, Salwender, Hans, Sonneveld, Pieter, Symeonidis, Anargyros, Toftmann Hansen, Charlotte, Tuglular, Tulin, Unal, Ali, Vlummens, Philip, Vural, Filiz, Wu, Ka Lung, Zweegman, Sonja, Dimopoulos, Meletios A, Terpos, Evangelos, Symeonidis, Argiris, Oriol, Albert, Mateos, Maria-Victoria, Einsele, Hermann, Orfanidis, Ioannis, Ahmadi, Tahamtan, Ukropec, Jon, Kampfenkel, Tobias, Schecter, Jordan M, Qiu, Yanping, Amin, Himal, Vermeulen, Jessica, and Carson, Robin

Published
2021
Full Text
View/download PDF

29. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis

Author

Bringhen, Sara, Pour, Ludek, Vorobyev, Vladimir, Vural, Filiz, Warzocha, Krzysztof, Benboubker, Lotfi, Koh, Youngil, Maisnar, Vladimir, Karlin, Lionel, Pavic, Michel, Campana, Frank, Le Guennec, Solenn, Menas, Fatima, van de Velde, Helgi, and Richardson, Paul G.

Published
2021
Full Text
View/download PDF

31. Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital.

Author

Lan, Caroline Le, Belot, Aurélien, Golfier, Camille, Audin, Bérénice, Sesques, Pierre, Bernier, Adeline, Safar, Violaine, Ferrant, Emmanuelle, Lazareth, Anne, Lequeu, Hélène, Karlin, Lionel, Ghergus, Dana, Maarek, Alizée, Aussedat, Guillaume, Idlhaj, Maryam, Salles, Gilles, Cherblanc, Fanny, Bachy, Emmanuel, and Ghesquieres, Hervé

Subjects
TEACHING hospitals, HIV infections
Abstract

The article discusses the evaluation of participation and recruitment bias in a real-world data (RWD) study called REALYSA, which focuses on newly diagnosed lymphoma patients. The study found that 54% of patients were included in the program, and factors such as age, gender, lymphoma subtype, performance status, and comorbidities were analyzed. The findings provide insights into patient participation in RWD programs and contribute to the understanding of lymphoma treatment strategies. The study also found that certain factors, such as disease aggressiveness and management approach, influenced the inclusion rate in the program. However, the study had limitations and further research is needed to better understand selection bias in real-world lymphoma cohorts. [Extracted from the article]

Published
2024
Full Text
View/download PDF

32. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Author

Lonial, Sagar, Lee, Hans C, Badros, Ashraf, Trudel, Suzanne, Nooka, Ajay K, Chari, Ajai, Abdallah, Al-Ola, Callander, Natalie, Lendvai, Nikoletta, Sborov, Douglas, Suvannasankha, Attaya, Weisel, Katja, Karlin, Lionel, Libby, Edward, Arnulf, Bertrand, Facon, Thierry, Hulin, Cyrille, Kortüm, K Martin, Rodríguez-Otero, Paula, Usmani, Saad Z, Hari, Parameswaran, Baz, Rachid, Quach, Hang, Moreau, Philippe, Voorhees, Peter M, Gupta, Ira, Hoos, Axel, Zhi, Eric, Baron, January, Piontek, Trisha, Lewis, Eric, Jewell, Roxanne C, Dettman, Elisha J, Popat, Rakesh, Esposti, Simona Degli, Opalinska, Joanna, Richardson, Paul, and Cohen, Adam D

Published
2020
Full Text
View/download PDF

33. Daratumumab Carfilzomib Lenalidomide and Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma

Author

Touzeau, Cyrille, primary, Perrot, Aurore, additional, Hulin, Cyrille, additional, Manier, Salomon, additional, Macro, Margaret, additional, Chretien, Marie-Lorraine, additional, Karlin, Lionel, additional, Escoffre, Martine, additional, Jacquet, Caroline, additional, Tiab, Mourad, additional, Leleu, Xavier, additional, Avet-Loiseau, Hervé, additional, Jobert, Alexandra, additional, Planche, Lucie, additional, Corre, Jill, additional, and Moreau, Philippe, additional

Published
2024
Full Text
View/download PDF

34. Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series

Author

Forgeard, Nathalie, primary, Elessa, Dikélélé, additional, Carpinteiro, Alexander, additional, Belhadj, Karim, additional, Minnema, Monique, additional, Roussel, Murielle, additional, Huart, Antoine, additional, Javaugue, Vincent, additional, Pascal, Laurent, additional, Royer, Bruno, additional, Talbot, Alexis, additional, Gounot, Romain, additional, Hegenbart, Ute, additional, Schonland, Stefan, additional, Karlin, Lionel, additional, Harel, Stéphanie, additional, Kastritis, Efstathios, additional, Bridoux, Frank, additional, Jaccard, Arnaud, additional, and Arnulf, Bertrand, additional

Published
2024
Full Text
View/download PDF

35. Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma and 1–3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 Cartitude-4 Trial

Author

Sidiqi, M Hasib, primary, Corradini, Paolo, additional, Purtill, Duncan, additional, Einsele, Hermann, additional, Dhakal, Binod, additional, Karlin, Lionel, additional, Manier, Salomon, additional, Iida, Shinsuke, additional, Giebel, Sebastian, additional, Harrison, Simon J, additional, Lipe, Brea, additional, Khan, Dr. Abdullah Mohammad, additional, Schecter, Jordan M, additional, Jackson, Carolyn C, additional, Yeh, Tzu-min, additional, Banerjee, Arnob, additional, Deraedt, William, additional, Lendvai, Nikoletta, additional, Lonardi, Carolina, additional, Slaughter, Ana, additional, Li, Katherine, additional, Chen, Diana, additional, Gilbert, Jane, additional, Roccia, Tito, additional, Zhao, Man, additional, Patel, Nitin, additional, Florendo, Erika, additional, Koneru, Mythili, additional, Filho, Octavio Costa, additional, Geng, Dong, additional, San-Miguel, Jesús, additional, and Yong, Kwee, additional

Published
2024
Full Text
View/download PDF

36. The EMMY Longitudinal, Cohort Study: Real-World Data to Describe Multiple Myeloma Management and Outcomes as More Therapeutic Options Emerge

Author

Decaux, Olivier, primary, Garlantézec, Ronan, additional, Belhadj-Merzoug, Karim, additional, Macro, Margaret, additional, Frenzel, Laurent, additional, Perrot, Aurore, additional, moreau, Philippe, additional, Royer, Bruno, additional, Caillot, Denis, additional, Leleu, Xavier, additional, Mohty, Mohamad, additional, Karlin, Lionel, additional, Feugier, Pierre, additional, Rigaudeau, Sophie, additional, Fontan, Jean, additional, Sonntag, Cécile, additional, Vincent, Laure, additional, Chalopin, Thomas, additional, Avet-Loiseau, Hervé, additional, Maarouf, Zakaria, additional, Chanaz, Louni, additional, Texier, Nathalie, additional, and Hulin, Cyrille, additional

Published
2024
Full Text
View/download PDF

38. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Author

Nicol, Andrew, Grigoriadis, George, Catalano, John, LeBlanc, Richard, Elemary, Mohamed, Bahlis, Nizar, Facon, Thierry, Karlin, Lionel, Ribrag, Vincent, Attal, Michel, Goldschmidt, Hartmut, Engelhardt, Monika, Weisel, Katja, Mackensen, Andreas, Nagler, Arnon, Ben Yehuda, Dina, Avivi, Irit, Benyamini, Noam, Magen-Nativ, Hila, Palumbo, Antonio, Cavo, Michele, Tobinai, Kensei, Iida, Shinsuke, Chou, Takaai, Suzuki, Kenshi, Kosugi, Hiroshi, Taniwaki, Masafumi, Sunami, Kazutaka, Matsumoto, Morio, Ando, Kiyoshi, Ganly, Peter, Blacklock, Hilary, Simpson, David, George, Anupkumar, Schjesvold, Fredrik, Gjertsen, Bjorn, Lahuerta, Juan, Blade, Joan, Oriol Rocafiguera, Albert, Mateos, Maria, Rodriguez-Otero, Paula, Larson, Sarah, Atanackovic, Djordje, Devarakonda, Srinivas, Bitran, Jacob, Zonder, Jeffrey, Morganstein, Neil, Hay, Mohammad, Chanan-Khan, Asher, Saylors, Gene, Kio, Ebenezer, Oliff, Ira, Kirkel, Dean, Shtivelband, Mikhail, Yuen, Carrie, Yee, Andrew, Shah, Jatin, Htut, Myo, Raza, Shahzad, Chhabra, Saurabh, Stiff, Patrick, Hari, Parameswaran, Bank, Bruce, Malek, Ehsan, Gasparetto, Cristina, Faroun, Ycaoub, Sherbenou, Daniel, Kreisle, William, Singhal, Seema, Rosenblatt, Jacalyn, Usmani, Saad, Lee, Wes, Safah, Hana, Lutzky, Jose, Suh, Jason, Pan, Dorothy, Baron, Ari, Manges, Robert, Steis, Ronald, Oliveira, Moacyr, Moreb, Jan, Callander, Natalie, Anz, Bertrand, Raptis, Anastasios, Stampleman, Laura, Melear, Jason, Boyd, Thomas, Garbo, Lawrence, Klein, Leonard, Shao, Spencer, Lyons, Roger, McIntyre, Kristi, Tarantolo, Stefano, Yasenchak, Christopher, Yimer, Habte, Mateos, Maria-Victoria, Oriol, Albert, Larocca, Alessandra, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, San Miguel, Jesus, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, and Lonial, Sagar

Published
2019
Full Text
View/download PDF

39. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Author

Lim, Andrew, Grigoriadis, George, Walker, Trish, Nicol, Andrew, LeBlanc, Richard, Reece, Donna, Elemary, Mohamed, Boudreault Pedneault, Jean Samuel, Karlin, Lionel, Facon, Thierry, Attal, Michel, Weisel, Katja, Engelhardt, Monika, Mackensen, Andreas, Quinn, John, Avivi, Irit, Cohen, Amos, Magen-Nativ, Hila, Benyamini, Noam, Cavo, Michele, Larocca, Alessandra, Takezako, Naoki, Suzuki, Kenshi, Kosugi, Hiroshi, Matsumoto, Morio, Iida, Shinsuke, Ishikawa, Takayuki, Kondo, Yukio, Sunami, Kazutaka, Ando, Kiyoshi, Teshima, Takanori, Chou, Takaaki, Iwasaki, Hiromi, Miki, Hirokazu, Matsumura, Itaru, Onishi, Yasushi, Izutsu, Koji, Kizaki, Masahiro, George, Anupkumar, Blacklock, Hillary, Simpson, David, Schjesvold, Fredrik, Waage, Anders, Samoilova, Olga, Nikitin, Evgeniy, Chagorova, Tatiana, McDonald, Andrew, Patel, Moosa, Oriol Rocafiguera, Albert, San Miguel Izquierdo, Jesus, Mateos, Maria, Streetly, Matthew, Forsyth, Peter, Jackson, Graham, Jenkins, Stephen, Rifkin, Robert, Yimer, Habte, McCroskey, Robert, Martincic, Danko, Tarantolo, Stefano, Larson, Sarah, Faroun, Yacoub, Vaughn, Jennifer, Baz, Rachid, Saylors, Gene, Neppalli, Amarendra, Raptis, Anastasios, Fung, Henry, Janosky, Maxwell, Stevens, Don, Coleman, Morton, Costa, Dennis, Cross, Scott, Fanning, Suzanne, Berges, Daniel Farray, Harris, Thomas, Zackon, Ira, Atanackovic, Djordje, Lee, Kelvin, Oliff, Ira, Lee, Wes, Bensinger, William, Lutzky, Jose, Baron, Ari, Hayek, Fadi, Kirschner, Eli, Bharany, Neeraj, Overton, Lindsay, Mannem, Siva, Harroff, Allyson, Jain, Sharad, Roque, Tammy, McIntyre, Kristi, Yasencha, Christopher K, Houck, William, Usmani, Saad Zafar, Oriol, Albert, Rifkin, Robert M, Yimer, Habte Aragaw, McCroskey, Robert Donald, Lim, Andrew Boon Ming, Jagannath, Sundar, Lonial, Sagar, Ghori, Razi Uddin, Farooqui, Mohammed Z H, Marinello, Patricia, and San-Miguel, Jesus

Published
2019
Full Text
View/download PDF

41. Low non‐relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle‐Thérapie Cellulaire observational study

Author

Garderet, Laurent, Ouldjeriouat, Hafida, Bekadja, Mohamed‐Amine, Daguenet, Elisabeth, Bigot, Noemie, Vincent, Laure, Roos‐Weil, Damien, Vignon, Marguerite, Ikhlef, Souhila, Abraham, Julie, Escoffre‐Barbe, Martine, Lioure, Bruno, Nacer, Redhouane Ahmed, Lafon, Ingrid, Mariette, Clara, Karlin, Lionel, Morel, Pierre, Gilis, Lila, Le Ray, Emanuelle, and Blouet, Anaïse

Subjects
HEMATOPOIETIC stem cell transplantation, KIDNEY failure, KIDNEY transplantation, MULTIPLE myeloma, AUTOTRANSPLANTATION
Abstract

Summary: High‐dose melphalan followed by autologous haematopoietic stem cell transplantation is widely used in newly diagnosed multiple myeloma (MM) patients as upfront therapy. However, the safety and efficacy of transplantation in patients with renal insufficiency (RI) are controversial. We followed a multicentre (16 SFGM‐TC centres) prospective cohort of 50 newly diagnosed MM patients with a serum creatinine clearance of <40 mL/min at transplantation. Patients received a recommended dose of melphalan of 140 mg/m2. The primary end‐point was the non‐relapse mortality at Day 100. One death occurred during the first 100 days post‐transplant. The median time to neutrophil engraftment was 12 days and to platelet engraftment was 13 days. The haematological response improved in 69% of patients, with best responses from partial response (PR) to very good partial response (VGPR) (10%), from PR to complete response (CR)/stringent complete response (sCR) (16%), from VGPR to CR/sCR (39%) and from CR to sCR (2%). At 2 years, the overall survival was 84%, the progression‐free survival was 70% and the cumulative incidence of relapse was 20%. The renal response improved in 59% of patients, with the best renal responses post‐transplant being minimal (9%), partial (2%) and complete (48%). Autologous transplantation was safe and effective in myeloma patients with RI at transplant. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Low non‐relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle‐Thérapie Cellulaire observational study

Author

Garderet, Laurent, primary, Ouldjeriouat, Hafida, additional, Bekadja, Mohamed‐Amine, additional, Daguenet, Elisabeth, additional, Bigot, Noemie, additional, Vincent, Laure, additional, Roos‐Weil, Damien, additional, Vignon, Marguerite, additional, Ikhlef, Souhila, additional, Abraham, Julie, additional, Escoffre‐Barbe, Martine, additional, Lioure, Bruno, additional, Nacer, Redhouane Ahmed, additional, Lafon, Ingrid, additional, Mariette, Clara, additional, Karlin, Lionel, additional, Morel, Pierre, additional, Gilis, Lila, additional, Le Ray, Emanuelle, additional, Blouet, Anaïse, additional, Nguyen Quoc, Stéphanie, additional, Boffa, Jean Jacques, additional, Ronco, Pierre, additional, Lambert, Jerome, additional, and Cornillon, Jérôme, additional

Published
2023
Full Text
View/download PDF

43. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

Author

Garderet, Laurent, Kuhnowski, Frederique, Berge, Benoit, Roussel, Murielle, Escoffre-Barbe, Martine, Lafon, Ingrid, Facon, Thierry, Leleu, Xavier, Karlin, Lionel, Perrot, Aurore, Moreau, Philippe, Marit, Gerald, Stoppa, Anne-Marie, Royer, Bruno, Chaleteix, Carine, Tiab, Mourad, Araujo, Carla, Lenain, Pascal, Macro, Margaret, Voog, Eric, Benboubker, Lofti, Allangba, Olivier, Jourdan, Eric, Orsini-Piocelle, Frederique, Brechignac, Sabine, Eveillard, Jean-Richard, Belhadj, Karim, Wetterwald, Marc, Pegourie, Brigitte, Jaccard, Arnaud, Eisenmann, Jean-Claude, Glaisner, Sylvie, Mohty, Mohamad, Hulin, Cyrille, Loiseau, Herve Avet, Mathiot, Claire, and Attal, Michel

Published
2018
Full Text
View/download PDF

44. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Author

Perrot, Aurore, Lauwers-Cances, Valerie, Corre, Jill, Robillard, Nelly, Hulin, Cyrille, Chretien, Marie-Lorraine, Dejoie, Thomas, Maheo, Sabrina, Stoppa, Anne-Marie, Pegourie, Brigitte, Karlin, Lionel, Garderet, Laurent, Arnulf, Bertrand, Doyen, Chantal, Meuleman, Nathalie, Royer, Bruno, Eveillard, Jean-Richard, Benboubker, Lotfi, Dib, Mamoun, Decaux, Olivier, Jaccard, Arnaud, Belhadj, Karim, Brechignac, Sabine, Kolb, Brigitte, Fohrer, Cecile, Mohty, Mohamad, Macro, Margaret, Richardson, Paul G., Carlton, Victoria, Moorhead, Martin, Willis, Tom, Faham, Malek, Anderson, Kenneth C., Harousseau, Jean-Luc, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, Avet-Loiseau, Hervé, and Munshi, Nikhil

Published
2018
Full Text
View/download PDF

45. Genetically determined telomere length and multiple myeloma risk and outcome

Author

Giaccherini, Matteo, Macauda, Angelica, Orciuolo, Enrico, Rymko, Marcin, Gruenpeter, Karolina, Dumontet, Charles, Raźny, Malgorzata, Moreno, Victor, Buda, Gabriele, Beider, Katia, Varkonyi, Judit, Avet-Loiseau, Hervé, Martinez-Lopez, Joaquín, Marques, Herlander, Watek, Marzena, Sarasquete, Maria Eugenia, Andersen, Vibeke, Karlin, Lionel, Suska, Anna, Kruszewski, Marcin, Abildgaard, Niels, Dudziński, Marek, Butrym, Aleksandra, Nagler, Arnold, Vangsted, Annette Juul, Kadar, Katalin, Waldemar, Tomczak, Jamroziak, Krzysztof, Jacobsen, Svend Erik Hove, Ebbesen, Lene Hyldahl, Taszner, Michał, Mazur, Grzegorz, Lesueur, Fabienne, Pelosini, Matteo, Garcia-Sanz, Ramon, Jurczyszyn, Artur, Demangel, Delphine, Reis, Rui Manuel, Iskierka-Jażdżewska, Elżbieta, Markiewicz, Miroslaw, Gemignani, Federica, Subocz, Edyta, Zawirska, Daria, Druzd-Sitek, Agnieszka, Stępień, Anna, Alonso, M. Henar, Sainz, Juan, Canzian, Federico, and Campa, Daniele

Published
2021
Full Text
View/download PDF

46. POSTER: MM-374 Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Prior B-Cell Maturation Antigen (BCMA)- Directed Therapies: Pooled Analysis From MagnetisMM Studies

Author

Nooka, Ajay K., primary, Lesokhin, Alexander M., additional, Mohty, Mohamad, additional, Niesvizky, Ruben, additional, Maisel, Christopher, additional, Arnulf, Bertrand, additional, Larson, Sarah M., additional, Varshavsky-Yanovsky, Asya Nina, additional, Leleu, Xavier, additional, Karlin, Lionel, additional, Vesole, David H., additional, Bahlis, Nizar J., additional, de Larrea, Carlos Fernández, additional, Raje, Noopur, additional, Leip, Eric, additional, Conte, Umberto, additional, Elmeliegy, Mohamed, additional, Viqueira, Andrea, additional, and Manier, Salomon, additional

Published
2023
Full Text
View/download PDF

47. P-325 Standard of care (SOC) outcomes in the last 3 years in patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): the first pooled analysis of LocoMMotion and MoMMent trials

Author

Weisel, Katja, primary, Mateos, Maria-Victoria, additional, Garcia, Maria Esther Gonzalez, additional, Bittrich, Max, additional, Lindsey-Hill, Joanne, additional, De Stefano, Valerio, additional, Besemer, Britta, additional, Vincent, Laure, additional, Kirkpatrick, Suriya, additional, Karlin, Lionel, additional, Goldschmidt, Hartmut, additional, Conticello, Concetta, additional, Roeloffzen, Wilfried, additional, van de Donk, Niels, additional, Delforge, Michel, additional, Doyle, Margaret, additional, Gray, Kathleen, additional, Albrecht, Claire, additional, Strulev, Vadim, additional, Haddad, Imène, additional, Saarinen, Silva, additional, Mitchell, Lada, additional, Buyze, Jozefien, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

48. MM-374 Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Prior B-Cell Maturation Antigen (BCMA)-Directed Therapies: Pooled Analysis From MagnetisMM Studies

Author

Nooka, Ajay K., primary, Lesokhin, Alexander M., additional, Mohty, Mohamad, additional, Niesvizky, Ruben, additional, Maisel, Christopher, additional, Arnulf, Bertrand, additional, Larson, Sarah M., additional, Varshavsky-Yanovsky, Asya Nina, additional, Leleu, Xavier, additional, Karlin, Lionel, additional, Vesole, David H., additional, Bahlis, Nizar J., additional, de Larrea, Carlos Fernández, additional, Raje, Noopur, additional, Leip, Eric, additional, Conte, Umberto, additional, Elmeliegy, Mohamed, additional, Viqueira, Andrea, additional, and Manier, Salomon, additional

Published
2023
Full Text
View/download PDF

49. P-287 Isatuximab plus pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma in real life context in France: IMAGE subgroup analysis based on subgroups of interest

Author

Decaux, Olivier, primary, Fontan, Jean, additional, Perrot, Aurore, additional, Karlin, Lionel, additional, Touzeau, Cyrille, additional, Manier, Salomon, additional, Belhadj, Karim, additional, Trebouet, Adrien, additional, Zunic, Patricia, additional, Stoppa, Anne-Marie, additional, Tekle, Christina, additional, Gaucher, Marianne, additional, and Leleu, Xavier, additional

Published
2023
Full Text
View/download PDF

50. P-302 Anchor (OP-104): melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/ refractory multiple myeloma (RRMM) – final efficacy and safety results

Author

Ocio, Enrique, primary, Efebera, Yvonne, additional, Hájek, Roman, additional, Straub, Jan, additional, Maisnar, Vladimir, additional, Eveillard, Jean-Richard, additional, Karlin, Lionel, additional, Mateos, Maria-Victoria, additional, Oriol, Albert, additional, Ribrag, Vincent, additional, Richardson, Paul, additional, Norin, Stefan, additional, Obermüller, Jakob, additional, Bakker, Nicolaas, additional, and Pour, Ludek, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results